ZBTB42 and thymoma: According to Figure 1A, the expression of ZBTB42 is slightly increased in breast invasive carcinoma (BRCA), glioblastoma multiforme (GBM), ovarian serous cystadenocarcinoma (OV), Prostate adenocarcinoma (PRAD), thymoma (THYM), and uterine corpus endometrial carcinoma (UCEC), while it is also increased in many other tumors including Brain Low Grade Glioma (LGG).